Quarterly ResultAug 13, 2026, 07:41 AM
Indaptus Q2 Net Loss $1.79M; Raises $12M in Private Placement
AI Summary
Indaptus Therapeutics reported a net loss of $1.79 million for the three months ended June 30, 2026, a significant improvement from $5.23 million in the prior year. For the six months, the net loss was $4.34 million, down from $9.76 million. The company raised approximately $12.0 million through a private placement of common stock in June 2026 and converted all outstanding preferred stock into common shares during the first quarter of 2026. Despite a going concern warning, management believes it has sufficient liquidity to fund operations through June 30, 2027.
Key Highlights
- Net loss for Q2 2026 was $1.79 million, a decrease from $5.23 million in Q2 2025.
- Net loss for H1 2026 was $4.34 million, a decrease from $9.76 million in H1 2025.
- Cash and cash equivalents were $7.55 million as of June 30, 2026.
- Total assets increased to $11.99 million from $9.31 million at December 31, 2025.
- Raised $12.0 million gross proceeds from a private placement of common stock in June 2026.
- All outstanding preferred stock converted to 111 million common shares in Q1 2026.
- Research and development expenses decreased to $0.85 million in H1 2026 from $4.98 million in H1 2025.
- Company has sufficient liquidity to fund operations through June 30, 2027, despite going concern doubt.
Price Impact
More from INDP
More in Quarterly Result